Skip to main content
Premium Trial:

Request an Annual Quote

Empire Genomics Clinical Lab Gets CLIA Certification, New York Approval

NEW YORK (GenomeWeb News) – Empire Genomics today said that its clinical laboratory facility has received CLIA certification and has been approved by the New York State Department of Health.

As a result, Buffalo, New York-based Empire Genomics said it plans to offer assays based on biomarkers for myeloma and prostate cancers in 2014. The company licensed a genomic biomarker from Emory University in late 2012 for multiple myeloma to develop a companion diagnostic, and in May the firm was awarded a Small Business Innovation Research grant from the National Cancer Institute to develop the test.

In May also, it licensed a biomarker from Cornell University to develop a companion diagnostic for neuroendocrine prostate cancer, and in June, Empire Genomics, the University of Buffalo, and Life Technologies joined forces to develop CLIA-certified next-generation sequencing facilities in upstate New York.